FABRAZYME (agalsidase beta)
METABOLIC DISEASE ENZYME REPLACEMENT, FABRY'S DISEASE · FABRY DISEASE
GENZYME
Drug class
Metabolic Disease Enzyme Replacement, Fabry's Disease
Metabolic Disease Enzyme Replacement for Fabry's Disease is an administrative and clinical drug classification encompassing exogenous recombinant alpha-galactosidase A therapies, such as agalsidase beta and pegunigalsidase alfa. Read more about Metabolic Disease Enzyme Replacement, Fabry's Disease
3 drugs in this class 3 manufacturers
Drugs in Metabolic Disease Enzyme Replacement, Fabry's Disease
GALAFOLD (migalastat HCl)
METABOLIC DISEASE ENZYME REPLACEMENT, FABRY'S DISEASE · FABRY DISEASE
AMICUS THERAPEU
ELFABRIO (pegunigalsidase alfa-iwxj)
METABOLIC DISEASE ENZYME REPLACEMENT, FABRY'S DISEASE · FABRY DISEASE
CHIESI USA, INC
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement, Fabry's Disease preselected. Add indication or manufacturer filters there.
Metabolic Disease Enzyme Replacement for Fabry's Disease is an administrative and clinical drug classification encompassing exogenous recombinant alpha-galactosidase A therapies, such as agalsidase beta and pegunigalsidase alfa.
Agents in this class work by cellular uptake and lysosomal internalization, providing functional enzyme to catalyze the breakdown of glycosphingolipids, predominantly globotriaosylceramide.
This therapeutic class is indicated specifically for the management of Fabry disease, an X-linked lysosomal storage disorder, to prevent substrate accumulation and attenuate progressive multiorgan dysfunction across the renal, cardiovascular, and nervous systems.
-
fda.gov
Metabolic Disease Enzyme Replacement for Fabry's Disease is an administrative and clinical drug classification encompassing exogenous recombinant alpha-galactosidase A therapies, such as agalsidase beta and pegunigalsidase alfa
-
practicalneurology.com
Metabolic Disease Enzyme Replacement for Fabry's Disease is an administrative and clinical drug classification encompassing exogenous recombinant alpha-galactosidase A therapies, such as agalsidase beta and pegunigalsidase alfa
-
nhpri.org
Metabolic Disease Enzyme Replacement for Fabry's Disease is an administrative and clinical drug classification encompassing exogenous recombinant alpha-galactosidase A therapies, such as agalsidase beta and pegunigalsidase alfa
-
fda.gov
Agents in this class work by cellular uptake and lysosomal internalization, providing functional enzyme to catalyze the breakdown of glycosphingolipids, predominantly globotriaosylceramide This therapeutic class is indicated specifically for the management of Fabry disease, an X-linked lysosomal storage disorder, to prevent substrate accumulation and attenuate progressive multiorgan dysfunction across the renal, cardiovascular, and nervous systems
-
fabrydiseasenews.com
Agents in this class work by cellular uptake and lysosomal internalization, providing functional enzyme to catalyze the breakdown of glycosphingolipids, predominantly globotriaosylceramide This therapeutic class is indicated specifically for the management of Fabry disease, an X-linked lysosomal storage disorder, to prevent substrate accumulation and attenuate progressive multiorgan dysfunction across the renal, cardiovascular, and nervous systems
-
fda.gov
Agents in this class work by cellular uptake and lysosomal internalization, providing functional enzyme to catalyze the breakdown of glycosphingolipids, predominantly globotriaosylceramide
-
nih.gov
This therapeutic class is indicated specifically for the management of Fabry disease, an X-linked lysosomal storage disorder, to prevent substrate accumulation and attenuate progressive multiorgan dysfunction across the renal, cardiovascular, and nervous systems
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.